4889 Stock Overview
Engages in the development and commercialization of pharmaceuticals and medical devices in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Renascience Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥342.00 |
| 52 Week High | JP¥584.00 |
| 52 Week Low | JP¥328.00 |
| Beta | 0.76 |
| 11 Month Change | -5.00% |
| 3 Month Change | -10.24% |
| 1 Year Change | -37.70% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -58.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4889 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -9.8% | 4.7% | 2.9% |
| 1Y | -37.7% | 7.5% | 20.0% |
Return vs Industry: 4889 underperformed the JP Pharmaceuticals industry which returned 7.5% over the past year.
Return vs Market: 4889 underperformed the JP Market which returned 20% over the past year.
Price Volatility
| 4889 volatility | |
|---|---|
| 4889 Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 3.9% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 2.0% |
Stable Share Price: 4889 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4889's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 3 | Koji Naito | www.renascience.co.jp |
Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets that is in Phase 3 clinical trials; RS5441, a PAI-1 inhibitor for use in dermatological diseases that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder, which is in Phase 2 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions.
Renascience Inc. Fundamentals Summary
| 4889 fundamental statistics | |
|---|---|
| Market cap | JP¥4.35b |
| Earnings (TTM) | -JP¥258.00m |
| Revenue (TTM) | JP¥194.00m |
22.4x
P/S Ratio-16.9x
P/E RatioIs 4889 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4889 income statement (TTM) | |
|---|---|
| Revenue | JP¥194.00m |
| Cost of Revenue | JP¥29.00m |
| Gross Profit | JP¥165.00m |
| Other Expenses | JP¥423.00m |
| Earnings | -JP¥258.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 08, 2024
| Earnings per share (EPS) | -20.30 |
| Gross Margin | 85.05% |
| Net Profit Margin | -132.99% |
| Debt/Equity Ratio | 22.2% |
How did 4889 perform over the long term?
See historical performance and comparison